IMFINZI (durvalumab)

TherapyAstraZeneca

IMFINZI (durvalumab) by AstraZeneca is a PD-L1–directed immunotherapy used across multiple tumor types.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and IMFINZI. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where IMFINZI is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Endometrial Carcinoma (EC) Solid Tumor · Endometrium	deficient mismatch repair (dMMR) proteins MLH1, PMS2, MSH2 and MSH6		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for IMFINZI.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering IMFINZI for eligible patients.

Test

Ventana MMR RxDx Panel

Ventana Medical Systems, Inc. (Roche Diagnostics)

Method

IHC

Specimen

Tissue (FFPE)

1 approvalView test profile →

This view is scoped to IMFINZI (durvalumab). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.